OTC · Drug Manufacturers - Specialty & Generic

China Medical System Holdings Limited (CHSYF) Stock

$1.57 +0.00% OTC: CHSYF Healthcare

China Medical System Holdings Limited functions as an investment holding enterprise with a primary focus on the pharmaceutical sector within the People's Republic of China. The company's core activities involve the development, marketing, and distribution of a comprehensive range of pharmaceutical products.

Valuation

MetricValue
Price$1.57
Market Cap$3.80B
P/E Ratio17.84
P/B Ratio1.51
P/S Ratio3.22
EPS (TTM)$0.09
52-Week High$1.64
52-Week Low$0.93
Dividend Yield2.55%

Financials & Margins

MetricValue
ROE8.65%
ROA7.75%
ROCE8.90%
Gross Margin71.50%
Operating Margin19.22%
Net Margin18.13%
Debt/Equity0.04
Current Ratio6.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$8.3B$9.2B$8.0B$7.5B$8.0B
Operating Profit$3.2B$3.6B$2.7B$1.7B$1.5B
Net Profit$3.0B$3.3B$2.4B$1.6B$1.4B
EPS$1.22$1.33$0.98$0.67$0.60
Op Margin37.8%38.8%33.9%23.2%19.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$15.8B$17.8B$17.7B$18.0B$19.2B
Total Liabilities$3.0B$3.0B$2.2B$1.6B$1.7B
Cash$3.4B$4.4B$4.3B$3.7B$2.7B
Borrowings$1.7B$1.8B$1.3B$861.0M$690.0M

Latest News

Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases PR Newswire · Jul 13, 2026 CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies GlobeNewswire · Jun 22, 2026 CMS's (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions GlobeNewswire · Jun 8, 2026 CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer® GlobeNewswire · Apr 27, 2026 CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China GlobeNewswire · Apr 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$2.5B$3.6B$2.5B$1.3B$758.0M
Investing Cash Flow$-1.7B$-1.7B$-760.0M$-1.1B$-1.5B
Financing Cash Flow$-181.0M$-54.0M$-236.0M$-262.0M$69.0M
Net Cash Flow$717.0M$991.0M$-65.0M$-605.0M$-1.0B
Free Cash Flow$2.3B$3.0B$2.2B$813.0M$244.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-2.35
EV / EBITDA13.40
FCF Yield0.92%
Quick Ratio5.78
Interest Coverage177.97
Return 1Y33.89%
Return 3Y167.48%
Return 5Y268.50%

Ownership

Insiders Held48.28%
Institutions Held25.88%
Institutions Float Held50.04%
Institutional HolderSharesReport Date
Pacer Advisors, Inc.161,4002025-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About China Medical System Holdings Limited

China Medical System Holdings Limited functions as an investment holding enterprise with a primary focus on the pharmaceutical sector within the People's Republic of China. The company's core activities involve the development, marketing, and distribution of a comprehensive range of pharmaceutical products. Its diverse portfolio addresses a wide array of medical conditions, offering treatments for cardiovascular issues (such as Plendil for hypertension and Imdur for heart disease), mental health disorders (including Deanxit for depression and anxiety), and various gastrointestinal ailments (like Ursofalk for gallstones and Salofalk for inflammatory bowel conditions). Furthermore, its therapeutic range extends to solutions for acute heart failure (XinHuoSu), numerous infections (e.g., DanShenTong capsules), respiratory illnesses (YiNuoShu), liver cancer (Ganfule capsules), osteoporosis (Elcatonin injection), and dermatological fungal conditions (Lamisil tablets), among many others. Beyond its principal pharmaceutical operations, the company also maintains interests in agriculture and livestock. Established in 1995, China Medical System Holdings Limited is based in North Point, Hong Kong, and operates as a subsidiary of Treasure Sea Limited.

China Medical System Holdings Limited is headquartered in HK.

China Medical System Holdings Limited (CHSYF) stock trades at $1.57 with a market capitalization of $3.80B. The stock is valued at a price-to-earnings (P/E) ratio of 17.84, price-to-book of 1.51, price-to-sales of 3.22. Over the past 52 weeks the stock has ranged between $0.93 and $1.64, and currently trades 4.3% below its 52-week high. It pays a dividend yielding 2.55%.

On profitability, China Medical System Holdings Limited generates a return on equity (ROE) of 8.65%, return on capital employed of 8.90%, an operating margin of 19.22%, a net profit margin of 18.13%.

Official website: www.cms.net.cn

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides